Adrenergic agonist: Difference between revisions

Jump to navigation Jump to search
Matt Pijoan (talk | contribs)
m Protected "Adrenergic agonist": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))
 
WikiBot (talk | contribs)
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)
Line 3: Line 3:
{{CMG}}
{{CMG}}


{{Editor Join}}
 


==Overview==
==Overview==
Line 65: Line 65:
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Drugs]]
[[Category:Drugs]]
{{SIB}}
 
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 20:45, 8 August 2012

Cardiology Network

Discuss Adrenergic agonist further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

WikiDoc Resources for Adrenergic agonist

Articles

Most recent articles on Adrenergic agonist

Most cited articles on Adrenergic agonist

Review articles on Adrenergic agonist

Articles on Adrenergic agonist in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Adrenergic agonist

Images of Adrenergic agonist

Photos of Adrenergic agonist

Podcasts & MP3s on Adrenergic agonist

Videos on Adrenergic agonist

Evidence Based Medicine

Cochrane Collaboration on Adrenergic agonist

Bandolier on Adrenergic agonist

TRIP on Adrenergic agonist

Clinical Trials

Ongoing Trials on Adrenergic agonist at Clinical Trials.gov

Trial results on Adrenergic agonist

Clinical Trials on Adrenergic agonist at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Adrenergic agonist

NICE Guidance on Adrenergic agonist

NHS PRODIGY Guidance

FDA on Adrenergic agonist

CDC on Adrenergic agonist

Books

Books on Adrenergic agonist

News

Adrenergic agonist in the news

Be alerted to news on Adrenergic agonist

News trends on Adrenergic agonist

Commentary

Blogs on Adrenergic agonist

Definitions

Definitions of Adrenergic agonist

Patient Resources / Community

Patient resources on Adrenergic agonist

Discussion groups on Adrenergic agonist

Patient Handouts on Adrenergic agonist

Directions to Hospitals Treating Adrenergic agonist

Risk calculators and risk factors for Adrenergic agonist

Healthcare Provider Resources

Symptoms of Adrenergic agonist

Causes & Risk Factors for Adrenergic agonist

Diagnostic studies for Adrenergic agonist

Treatment of Adrenergic agonist

Continuing Medical Education (CME)

CME Programs on Adrenergic agonist

International

Adrenergic agonist en Espanol

Adrenergic agonist en Francais

Business

Adrenergic agonist in the Marketplace

Patents on Adrenergic agonist

Experimental / Informatics

List of terms related to Adrenergic agonist

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

An adrenergic is a drug, or other substance, which has effects similar to, or the same as, epinephrine (adrenaline). Thus, they are a kind of sympathomimetic agents. Alternatively, it may refer to something which is susceptible to epinephrine, or similar substances, such as a biological receptor (specifically, the adrenergic receptors).

Beta blockers block the action of epinephrine and norepinephrine in the body. Adrenergic drugs either stimulate a response (agonists) or inhibit a response (antagonists). The five categories of adrenergic receptors are: α1, α2, β1, β2, and β3, and agonists vary in specificity between these receptors, and may be classified respectively. However, there are also other mechanisms of adrenergic agonism. Epinephrine and norepinephrine are endogenous and broad-spectrum. More selective agonists are more useful in pharmacology.

α1 agonists

α1 agonists: stimulates phospholipase C activity. (vasoconstriction and mydriasis; used as vasopressors, nasal decongestants & eye exams). Selected examples are:

α2 agonists

α2 agonists: inhibits adenylyl cyclase activity. (reduce brainstem vasomotor center-mediated SNS activation; used as antihypertensives, sedatives & treatment of opiate & alcohol withdrawal symptoms). Selected examples are:

  • Clonidine (mixed alpha2-adrenergic and imidazoline-I1 receptor agonist)
  • Guanfacine (preference for alpha2A-subtype of adrenoceptor)
  • Guanabenz (most selective agonist for alpha2-adrenergic as opposed to imidazoline-I1)
  • Guanoxabenz (metabolite of guanabenz)
  • Guanethidine (periferal alpha2-receptor agonist)

β1 agonists

β1 agonists: stimulates adenylyl cyclase activity; opening of calcium channel. (cardiac stimulants; used to treat cardiogenic shock, acute heart failure, bradyarrhythmias). Selected examples are:

β2 agonists

β2 agonists: stimulates adenylyl cyclase activity; closing of calcium channel (smooth muscle relaxants; used to treat asthma and COPD). Selected examples are:

Other mechanisms

See also

External links


Template:Adrenergic and dopaminergic agents Template:Receptor agonists and antagonists


Template:WikiDoc Sources